温馨提示：每逢春夏季，因天气潮湿或炎热，产品易变质，请把产品存放于冰箱中。开封后，请在30天(含抗氧化剂）或60天(不含抗氧化剂)内，把本产品服用完，否则产品可能因为环境湿度过大或/和环境温度过高而变质。
本产品为膳食补充剂dietary supplement，每瓶含 120 粒片剂， 提供五种植物精华：大豆异黄酮、黑升麻、当归、甘草、黄荆草梅精华。有助于舒缓女性经期更年期症状、潮热，增强活力。
成分
（120 粒）3 粒片剂含：
豆异黄酮（来自 2.1 克非转基因大豆异黄酮复合物）...... 46 毫克
黑升麻根标准提取物 ...... 160 毫克
当归根提取物...... 150 毫克
甘草根提取物...... 150 毫克
黄荆草梅精华 ...... 100 毫克
无防腐剂，无人工调味剂或着色剂，无肤质gluten，无小麦，无奶制品，无酵母，无糖。
建议服用方法
成年人每日服用 3 粒。或遵守专业保健人员指导。放置于孩童无法拿取处。
本产品和全能一起服用，效果最佳。
注意：如果正在怀孕、将要怀孕、正在哺乳，请不要使用。
保藏
在5-20摄氏度，干燥避光处保藏。
功效†
大豆异黄酮 Soy Isoflavone
是一系列的植物雌激素化合物，它们来自植物，在结构和/或功能上类似于动物雌激素。在人类饮食中，大豆和豆制品是大豆异黄酮的最丰富来源。流行病学研究已经发现，摄入高豆类食品的个人，常常有着数种健康优势。许多实验室研究和临床研究，研 究了豆类食品的健康益处，已经找到大豆异黄酮，就是导致与豆类食品相关的健康效果的关键成分。大豆异黄酮，既有柔和的雌激素功能，也有温和的抗雌激素效 果，这种两面的平衡能力，可能让其有能力调节更年期症状以及支持维护骨骼矿物质密度。大豆异黄酮还能帮助保护心血管系统，支持免疫系统，抑制血管生成 （angiogenesis，一个与肿瘤血管增长相关的词），还能作为抗氧化剂抗击氧化损伤。
黑升麻 Black cohosh
是一种植物。它的根被用于药用。它最初是被北美印第安人用于药用，后来介绍给欧洲殖民者。在1950年代，黑升麻成为欧洲对付女性健康问题的方法。从那时起，它已经普遍被用于帮助更年期症状（比如潮热，易怒，情绪波动，睡眠不佳），更年期前综合症prementrual syndrome，痛苦的经期，青春痘，骨质疏松osteoprosis。根据加拿大卫生部（http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=44&lang=eng），黑升麻帮助舒缓经期疼痛，帮助舒缓风湿性肌肉和关节疼痛，帮助舒缓神经痛（比如坐骨神经痛），帮助舒缓神经紧张，帮助舒缓经前症状，帮助舒缓绝经相关症状。
当归Dong Qui
是一种植物，被用来对付月经痉挛，经前综合症PMS，以及更年期综合症（引用自www.webmd.com）。根据加拿大卫生部（http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=842&lang=eng），当归可用来增强活力，可以平衡及补血。
黄荆草梅Vitex
是荆的果实，它有时被称为“女性之草”。它被用于经期不规律，经前综合症PMS， 更严重的经前烦躁症PMDD，以及经期症状。它还被用于“块状”（纤维囊肿）的乳房，女性不孕，预防那些女性激素黄体酮（孕激素progesterone)低的女性的流产，控制出血，并帮助身体在分娩后排出胎盘，增加乳汁（引用自www.webmd.com）。根据加拿大卫生部（http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=274&lang=eng），黄荆草梅在草药学中，被用来帮助舒缓经前症状，荷尔蒙稳定剂来帮助稳定经期不规律，帮助舒缓月经相关症状如潮热。
甘草Licorice
被用在草药“芍药甘草汤Shakuyaku-kanzo-to”中，来提高患有荷尔蒙疾病多囊卵巢综合症polycystic ovary syndrome的女性的怀孕机率（引用自www.webmd.com）。
加拿大卫生部认可的大豆异黄酮的功能：
http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=rcie&lang=eng
http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=soy_extra_isolate&lang=eng
更多关于黑升麻的信息，请看美国知名营养成分及药物成分数据库网站：
http://www.webmd.com/vitamins-supplements/ingredientmono-857-BLACK+COHOSH.aspx?activeIngredientId=857&activeIngredientName=BLACK+COHOSH&source=3
更多关于当归的信息，请看美国知名营养成分及药物成分数据库网站：
http://www.webmd.com/vitamins-supplements/ingredientmono-936-DONG+QUAI.aspx?activeIngredientId=936&activeIngredientName=DONG+QUAI&source=3
（去“百度翻译” http://fanyi.baidu.com/，输入以上英文网站，翻译为中文）
† These statements have not been evaluated by the Food and Drug Administration.This product is not intended to diagnose, treat, cure, or prevent any disease.
Cautions/Warnings: Consult a health care practitioner if symptoms persist or worsen; if you are breastfeeding; if you have a liver disorder or develop symptoms of liver trouble; if you are taking blood thinners. Do not use if you are pregnant. Keep out of reach of children.
参考文献
Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med 1997;29:95-120.
Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998;91:6-11.
Baird DD, Umbach DM, Lansdell L, Hughes CL, Setchell KD, Weinberg CR, Haney AF, Wilcox AJ, McLachlan JA. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab 1995;80:1685-90.
Barnes S. Evolution of the health benefits of soy isoflavones. Proc Soc Exp Biol Med 1998;217:386-92.
Nestel PJ, Yamashita T, Sasahara T, Pomeroy S, Dart A, Komesaroff P, Owen A, Abbey M. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol 1997;17:3392-8.
Petrakis NL, Barnes S, King EB, Lowenstein J, Wiencke J, Lee MM, Miike R, Kirk M, Coward L. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev 1996;5:785-94.
Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW, Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68:1375S-1379S
Amato P, Christophe S, Mellon PL. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause 2002;9:145-50. View abstract.
Amsterdam JD, Yao Y, Mao JJ, Soeller I, Rockwell K, Shults J. Randomized, double-blind, placebo-controlled trial of Cimicifuga racemosa (black cohosh) in women with anxiety disorder due to menopause. J Clin Psychopharmacol 2009;29:478-83. View abstract.
Assessment of case reports connected to herbal medicinal products containing cimicifugae racemosa rhizoma (black cohosh, root). Doc. Ref. EMEA/269259/2006. Available at: www.emea.eu.int/pdfs/human/hmpc/26925806en.pdf (Accessed 30 November 2007).
Australian Adverse Drug Reactions Advisory Committee. Black cohosh and liver toxicity - an update. Aust Adv Drug Reactions Bull 2007;26:11.
Bai W, Henneicke-von Zepelin HH, Wang S, et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: A randomized, double blind, parallel-controlled study versus tibolone. Maturitas 2007;58:31-41. View abstract.
Bai WP, Wang SY, Liu JL, Geng L, Hu LN, Zhang ZL, Chen SL, Zheng SR. [Efficacy and safety of remifemin compared to tibolone for controlling of perimenopausal symptoms]. Zhonghua Fu Chan Ke Za Zhi 2009;44:597-600. View abstract.
Circosta, C., Pasquale, R. D., Palumbo, D. R., Samperi, S., and Occhiuto, F. Estrogenic activity of standardized extract of Angelica sinensis. Phytother.Res. 2006;20(8):665-669. View abstract.
Hudson TS, Standish L, Breed C, and et al. Clinical and endocrinological effects of a menopausal botanical formula. J Naturopathic Med 1998;7(1):73-77.
Kupfersztain, C., Rotem, C., Fagot, R., and Kaplan, B. The immediate effect of natural plant extract, Angelica sinensis and Matricaria chamomilla (Climex) for the treatment of hot flushes during menopause. A preliminary report. Clin Exp Obstet.Gynecol 2003;30(4):203-206. View abstract.
Ben-Arye, E., Oren, A., and Ben-Arie, A. [Herbal medicine in womens' life cycle]. Harefuah 2006;145(10):738-42, 782. View abstract.
Bergmann, J., Luft, B., Boehmann, S., Runnebaum, B., and Gerhard, I. [The efficacy of the complex medication Phyto-Hypophyson L in female, hormone-related sterility. A randomized, placebo-controlled clinical double-blind study]. Forsch Komplementarmed Klass.Naturheilkd. 2000;7(4):190-199. View abstract.
Bhargava, S. K. Antiandrogenic effects of a flavonoid-rich fraction of Vitex negundo seeds: a histological and biochemical study in dogs. J Ethnopharmacol. 1989;27(3):327-339. View abstract.
Blank A and Gerhard I. Agnus castus containing preparation on female sterility. Fact: Focus on Alternative and Complementary Therapies 1998;3(4):182.
Bleier W. Therapie von Zyklus- und Blutungsstorungen und weiteren endokrin bedingten Erkrankungen der Frau mit pflanzlichen Wirkstoffen. Zbl Gynakol 1959;81:701-709.
Bubenzer RH. Therapy with Agnus castus extract (Strotan
Ciotta, L., Pagano, I., Stracquadanio, M., Di, Leo S., Ando, A., and Formuso, C. [Psychic aspects of the premenstrual dysphoric disorders. New therapeutic strategies: our experience with Vitex agnus castus]. Minerva Ginecol. 2011;63(3):237-245. View abstract.
Coeugniet E. Premenstrual syndrome and its treatment. Arztezeitchr Naturheilverf 1986;27:619-622.
Dante, G. and Facchinetti, F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom.Obstet.Gynaecol. 2011;32(1):42-51. View abstract.
Dennehy, C. E. The use of herbs and dietary supplements in gynecology: an evidence-based review. J Midwifery Womens Health 2006;51(6):402-409. View abstract.
Dittmar FW. Premenstrual syndrome: treatment with a phytopharmaceutical [in German]. TW Gynakologie 1992;5(1):60-68.
Doll, M. [The premenstrual syndrome: effectiveness of Vitex agnus castus]. Med.Monatsschr.Pharm. 2009;32(5):186-191. View abstract.
Dugoua, J. J., Seely, D., Perri, D., Koren, G., and Mills, E. Safety and efficacy of chastetree (Vitex agnus-castus) during pregnancy and lactation. Can.J Clin Pharmacol. 2008;15(1):e74-e79. View abstract.
Eagon, P. K., Elm, M. S., and Hunter, D. S. Medicinal herbs: modulation of estrogen action. Era of Hope Mtg 2000;
Feldmann HU, Albrecht M, Lamertz M, and et al. The treatment of corpus Luteum insufficiency and premenstrual syndrome. Experience in a multicenter study under clinical practice conditions. [in German]. Gyne 1990;11(12):421-425.
Fersizoglou NE. Hormonale und thermographische veränderungen unter konservativer therapie der mastophathie. Vergleich von danazol, tamoxifen, lisurid, lynesterenol und einem phytopharmakon. Dissertation 1989;
Fikentscher, H. [Aetiology, diagnosis und therapy of mastopathy and mastodynia. Experiences of treatment with mastodynon (author's transl)]. Med Klin 8-26-1977;72(34):1327-1330. View abstract.
Fournier D and Grumbrecht C. Behandlung der mastopathie, mastodynie und des prämenstruellen syndroms. Verleich medikamentöser behandlung zu unbehandelten kontrollen. Therapiewoche 1987;37(5):430-434.
Freeman, E. W. Therapeutic management of premenstrual syndrome. Expert.Opin.Pharmacother. 2010;11(17):2879-2889. View abstract.
Fugh-Berman, A. and Kronenberg, F. Complementary and alternative medicine (CAM) in reproductive-age women: a review of randomized controlled trials. Reprod Toxicol. 2003;17(2):137-152. View abstract.
Armanini, D., Castello, R., Scaroni, C., Bonanni, G., Faccini, G., Pellati, D., Bertoldo, A., Fiore, C., and Moghetti, P. Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol.Reprod Biol 2007;131(1):61-67. View abstract.